Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Thrombolysis Using Tenecteplase (Metalyse®) in Cardiac Arrest - The TROICA Trial

Phase 3

Terminated

Conditions: Heart Arrest

First Posted Date: 2005-09-12

Last Posted Date: 2013-10-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1050

Registration Number: NCT00157261

Locations: 🇦🇹
Univ.-Klinik f. Notfallmedizin, Wien, Austria
🇧🇪
AZ VUB, Bruxelles, Belgium
🇧🇪
AZ Groeningen, Kortrijk, Belgium

and more 64 locations

1 Year Trial Telmisartan 80 mg Versus Valsartan 160 mg in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathies
Hypertension

First Posted Date: 2005-09-12

Last Posted Date: 2013-11-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 885

Registration Number: NCT00153023

Locations: 🇨🇿
District Hospital Tabor, Tabor, Czech Republic
🇫🇷
Hopital A.Mignot, Le Chesnay, France
🇨🇿
University Hospital Hradec Kralove, Hradec Kralove, Czech Republic

and more 91 locations

3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension

Phase 2

Completed

Conditions: Hypertension

First Posted Date: 2005-09-12

Last Posted Date: 2013-11-08

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 583

Registration Number: NCT00153049

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Taya-gun, Gunma, Japan

Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement

Phase 3

Completed

Conditions: Arthroplasty, Replacement, Knee
Thromboembolism

Interventions: Drug: Dabigatran Dose 1 - day 2 to completion
Drug: Dabigatran Dose 2 - day 2 to completion
Drug: Enoxaparin
Drug: Dabigatran Dose 1 - day 1
Drug: Dabigatran Dose 2 - day 1

First Posted Date: 2005-09-12

Last Posted Date: 2014-05-05

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2615

Registration Number: NCT00152971

Locations: 🇲🇽
1160.24.05009 Traumatologia, Planta Baja, Guadalajara, Jalisco, Mexico
🇺🇸
1160.24.01010 MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸
1160.24.01033 Bone and Joint Clinic of Houston, Houston, Texas, United States

and more 91 locations

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Phase 4

Completed

Conditions: Diabetic Nephropathies

First Posted Date: 2005-09-12

Last Posted Date: 2013-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 527

Registration Number: NCT00153088

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Yokohama, Kanagawa, Japan

Pramipexole (BI-Sifrol®) Orally Once Daily for 6 Weeks in Patients With Primary Restless Legs Syndrome

Phase 2

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-09-12

Last Posted Date: 2013-10-31

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 41

Registration Number: NCT00152997

Locations: 🇯🇵
Boehringer Ingelheim Investigational Site, Takatsuki, Osaka, Japan

Effect of Tiotropium Inhalation Capsules (Spiriva) on Exercise Tolerance in COPD Patients

Phase 3

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

First Posted Date: 2005-09-12

Last Posted Date: 2017-12-28

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 234

Registration Number: NCT00157235

Locations: 🇮🇹
Fondazione Don Gnocchi, Pozzolatico (FI), Italy
🇮🇹
Fondazione "S. Maugeri", Tradate (VA), Italy
🇮🇹
Arcispedale S. Anna, Ferrara, Italy

and more 8 locations

An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type

Phase 2

Completed

Conditions: Alzheimer Disease

First Posted Date: 2005-09-12

Last Posted Date: 2013-10-29

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 430

Registration Number: NCT00153010

Locations: 🇺🇸
Margolin Brain Institute, Fresno, California, United States
🇺🇸
Southwest Institute for Clinical Research, Rancho Mirage, California, United States
🇺🇸
North Michigan Neurology, Traverse City, Michigan, United States

and more 73 locations

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

Phase 3

Completed

Conditions: Restless Legs Syndrome

First Posted Date: 2005-09-12

Last Posted Date: 2013-11-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 224

Registration Number: NCT00152958

Locations: 🇩🇪
Clinpharm International GmbH & Co. KG, Berlin (Hellersdorf), Germany
🇩🇪
emovis GmbH, Berlin, Germany
🇩🇪
Paracelsus-Elena-Klinik, Kassel, Germany

and more 6 locations

Rt-PA in the Treatment of Acute Ischemic Stroke

Phase 3

Completed

Conditions: Cerebrovascular Accident

First Posted Date: 2005-09-12

Last Posted Date: 2014-05-16

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 821

Registration Number: NCT00153036

Locations: 🇦🇹
135.312.43007 Boehringer Ingelheim Investigational Site, Innsbruck, Austria
🇦🇹
135.312.43004 Boehringer Ingelheim Investigational Site, Graz, Austria
🇦🇹
135.312.43006 Boehringer Ingelheim Investigational Site, Salzburg, Austria

and more 139 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy